People trying to put a valuation on IMU for just its CF33/OnCARlytics need simply take one of the worlds leading cancer drugs and use a multiple of 5 times to get a low ball number for what we have.
Keytruda has annual revenues of just under $30 billion so a low ball offer will be $150 billion or over $20 AUD per share. That’s a LOW ball number so if it’s a takeover of our entire portfolio try $30 per share and it’s probably still a little low.
Enjoy the journey.
Why IMU is a multi multi bagger, page-20902
-
- There are more pages in this discussion • 4,761 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
